$LLY

AI Analysis

Generated on May 11, 2026

AI Score
74/ 100
Hold$LLY

Eli Lilly and Company

$LLYNYSEHealthcareMega-Cap

Eli Lilly discovers, develops, and markets pharmaceutical products, with leading positions in diabetes (Mounjaro), obesity (Zepbound), and oncology.

Market Cap
$720.0B
Revenue (TTM)
$41.3B
+32.0%
Net Income (TTM)
$9.4B
+68.0%
EPS (TTM)
$10.35
P/E Ratio
72.0
Dividend Yield
0.7%
52-Week Range
$600-$972
Beta
0.42
Dimension Scores
Fundamental
72
Technical
62
Sentiment
78
Risk / Reward
60
Momentum
82
FundTechSentRiskMome
Financial Health
Profitability
77strong
Growth
85strong
Liquidity
68strong
Solvency
74strong
Efficiency
70strong

Valuation, technical analysis, investment thesis, risk assessment and more for $LLY

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.